Programme
Speakers
Profile
KEYNOTE SPEAKER
Mr. How ti-hwei
Country President, AstraZeneca
Keynote Talk: Introduction to Singapore's Bio-Pharmaceuticals
Ti-Hwei is the Country President of AstraZeneca Singapore, a global, science-led pharmaceutical company, focused on the discovery, development and commercialisation of life-changing prescription medicines. He also serves as the President of the Singapore Association of Pharmaceutical Industries (SAPI), and the Chair of the European Chamber of Commerce (EuroCham) Healthcare Committee. He is also a member of the NUS Pharmacy Programme Advisory Board, and the Ngee Ann Polytechnic Life Sciences & Chemical Technology Advisory Committee. A Singapore national, Ti-Hwei holds a Bachelor of Science (Pharmacy) with Honours, and an MBA from the National University of Singapore. He completed his pre-registration Pharmacist training in National University Hospital before venturing into the private sector. Ti-Hwei has had more than 20 years of Commercial experience across the Pharmaceutical & FMCG industries and has spent the last 7 years in various General Management roles. Outside of Singapore, his career has seen him lived and worked in Thailand, the Philippines, Vietnam and Malaysia. He currently resides in Singapore with his wife and 2 teenage sons. He stays active playing tennis and mountain-biking.
PANEL DISCUSSION
Challenges in the Singapore Bio-Pharmaceutical Landscape
LET'S
DISCUSS
The bio-pharmaceutical industry is a maturing industry, now challenged with more generic competition and increasing regulatory expectations from governing bodies across the world. As a result, processes from the research all the way to the healthcare front are pursuing leaner, more efficient procedures. The question is, how does this pursuit affect the overall health of the landscape? In the opening panel discussion for Pheature 2019, we will be exploring the challenges in Singapore bio-pharmaceutical landscape as a case study.
​
Discussion Panel (from left to right):
-
Mr How Ti Hwei (Moderator)
-
Dr Keith Carpenter (Executive Director, A*Star Singapore)
-
Dr Alireza Hosseini (Chief Operating Officer, Singapore Biotech
TRACK SPEAKERS
DR Rachel Ee
Associate Professor
Department of Pharmacy, National University of Singapore
Presentation Topic: Moving from biologics to biosimilars to biobetters/biosuperiors
Biologics are a class of drugs that are produced using a living system, such as a microorganism, plant cell, or animal cell. Unlike “small molecule” drugs, they occupy a unique space in drug discovery and development. They are potent, more expensive, and complex in their therapeutic applications. It is projected that biologics and their equivalents (biosimilars) and successors (biobetters) will take up a much larger share in the drug market than small molecule drugs. In this session, I will focus on deconvoluting the confusing definitions surrounding this class of compounds and describe the prospective trends of this innovative therapeutic class.
dr alireza hosseini
Chief Operating Officer
Singapore Biotech
Presentation Topic: What makes a biosimilar? From design to market with Singapore Biotech
‘What makes a biosimilar’ takes you on the journey of a biosimilar's development. Starting from an overview of the market, Singapore Biotech will dive into start strategies and various considerations during the development process, before finishing on the regulatory and governing bodies approaches to provide a comprehensive position of what make a biosimilar and various benefits that they bring.
DR. Borna Parsons
Chief Scientific Officer
Singapore biotech
Presentation Topic: What makes a biosimilar? From design to market with Singapore Biotech
‘What makes a biosimilar’ takes you on the journey of a biosimilar's development. Starting from an overview of the market, Singapore Biotech will dive into start strategies and various considerations during the development process, before finishing on the regulatory and governing bodies approaches to provide a comprehensive position of what make a biosimilar and various benefits that they bring.
![IMG_7409[1].JPG.png](https://static.wixstatic.com/media/9cbb13_67d8bf6da81b46b19e8073d8e711ca56~mv2_d_1774_2292_s_2.png/v1/crop/x_0,y_274,w_1774,h_1743/fill/w_73,h_71,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/IMG_7409%5B1%5D_JPG.png)
MS CHERYL LIM YU LING
Ambulatory Care Pharmacist
Singapore General Hospital
Presentation Topic: Biosimilars in patient care
Biosimilars are biological products produced from living organisms that are highly similar to the reference product. Many biosimilars, to date, have been found to have no clinically meaningful difference from the originator biologics. With the patent of numerous originator biologics expiring in the near future, the biosimilars market are set to pressure price reduction and intense competition.
Mr Lin Xiang Liang
President
ESCO Healthcare
Presentation Topic: Development pipeline for biologics/biosimilars
Biosimilars/Biobetters require to be lower costs compared to originators to be attractive to healthcare systems. This presentation presents new novel and advanced process intensification to replace ATF to a novel Alternating Continuous Chromatography and continuous freeze drying as well as novel expression systems including plants as bioreactors and single domain antibodies which are the future of biobetters.